Poly ADP-ribose Polymerase (PARP) Staining for Immunohistological Investigation of Primary Breast Cancer by TSUKUDA Genki et al.
Showa Univ J Med Sci 25（2）, 83～91, June 2013
Poly ADP-ribose Polymerase（PARP）Staining for Immunohistological 
Investigation of Primary Breast Cancer
Genki TSUKUDA 1，2）, Yuko DATE 1）, Kunio ASONUMA 1）, 
Yusuke WADA 1）, Masayuki ISOZAKI 1，2）, Tomoko INAGAKI 1）, 
Mutsuko OMATU 3）, Toshiaki KUNIMURA3）, Seigo NAKAMURA4）, 
Miki KUSHIMA5）, Kazuhide KUMAGAI 2）and Toshio MOROHOSHI 1）
Abstract : Given that clinical trials of poly ADP-ribose polymerase（PARP）1 
inhibitors are underway, in the present study we investigated the prevalence of 
triple-negative breast cancer and PARP1 expression in patients with primary 
invasive breast cancer.  Immunohistological studies plus PARP staining were 
performed on samples from 206 primary breast cancer patients undergoing surgery 
at Showa University Hospital between January 2010 and May 2011.  Fifteen 
patients（7.3％）were found to have triple-negative breast cancer.  Hormone 
receptor-positive patients were significantly more likely to be PARP1 negative.  
There were no PARP1-negative patients in the triple-negative group.  However, 
there was no significant difference in the rate of PARP1 negativity between 
patients with triple-negative breast cancer and those with other breast cancer 
subtypes.  There were no PARP1-negative patients in the triple-negative breast 
cancer group.  Given that the effectiveness of PARP inhibitors has not been 
sufficiently established in clinical trials, a more in-depth analysis is required to 
determine the factors contributing to effective treatment.  Future studies should 
include more subjects with triple-negative breast cancer and those with BRCA 
mutations.
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Introduction
　In the past, the classification of breast cancer was based largely on conventional histo-
pathological diagnosis.  Recently, a hierarchical clustering method based on gene expression 
profiling was shown to be useful for predicting treatment responsiveness and outcomes 1-3）.  Using 
gene expression profiling, breast cancer can be classified into intrinsic subtypes through detailed 
gene expression analysis.  In clinical practice, immunohistochemistry（IHC）can be a useful 
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surrogate for the gene analysis used for tumor classification 4）.  Patients are classified into the 
following groups on the basis of tumor characteristics :（ⅰ）luminal A, consisting of patients who 
are positive for estrogen（ER）and/or progesterone（PR）receptors, but not human epidermal 
growth factor receptor 2（HER2）, and who have Ki67 levels ≥14％ ;（ⅱ）luminal B, consisting 
of patients who are ER and/or PR positive and either HER2 positive and/or with Ki67 levels 
≥14％ ;（ⅲ）HER2, consisting of patients who are HER-2 positive and ER and PR negative ; 
and（ⅲ）triple negative, comprising patients who are negative for all three receptors（ER, PR, 
and HER2）5）.
　Currently, the treatment for breast cancer is largely decided on the basis of hormone receptor
（HR）and HER2 status, with tumors classified into subtypes depending on the HR, HER2, 
and Ki67 status.  This classification has an important role in determining both treatment 
and prognosis.  For example, triple-negative breast cancer has a poor prognosis 6） and limited 
treatment options.  Therefore, there is an urgent need to develop new drugs for the treatment of 
triple-negative breast cancer.
　One of the characteristics of triple-negative breast cancer is that many of these tumors have 
DNA-repair defects in cells harboring BRCA mutations7）.  This has led to the development of 
poly ADP-ribose polymerase（PARP）inhibitors for the treatment of triple-negative breast cancer.
　PARP is an enzyme involved in the DNA repair process that was discovered independently 
by scientists in Japan and France approximately 40 years ago 8，9）.  The main role of PARP is to 
detect and repair DNA single-strand breaks.  Because tumor cells that are BRCA1 or BRCA2 
deficient exhibit defective homologous combination repair of DNA double-strand breaks, it was 
expected that inhibition of PARP may destabilize the genome, leading to cell apoptosis（Fig. 1）.
　In 2005, Farmer et al 11） and Bryant et al 12） reported that BRCA1- or BRCA2-defective cells 
have greater sensitivity to PARP inhibitors than wild-type cells.  These studies raised expectations 
for the clinical application of PARP inhibitors, leading to the start of clinical trials for familial 
breast cancer and familial ovarian cancer patients with BRCA mutations.
　Some studies demonstrated significantly greater PARP1 upregulation in triple-negative breast 
cancer than in normal tissues.  This observation was confirmed in a Phase Ⅱ clinical trial, 
the results of which were reported at a plenary session of the American Society of Clinical 
Oncology（ASCO）annual meeting in 2009 13）.  Although clinical trials of PARP inhibitors are 
currently underway, the effectiveness of these agents has not been sufficiently established as yet. 
The expression of the PARP1 in primary breast cancer  has many questions.
　The aim of the present study was to investigate the prevalence of breast cancer subtypes in a 
Japanese cohort to establish their clinicopathological features, as well as PARP expression.
Materials and Methods
　The subjects of the present study were 206 patients with primary invasive breast cancer 
who underwent surgery at Showa University Hospital between January 2010 and May 2011. 
Patients who were undergoing neoadjuvant therapies were excluded from the study.  The 
clinicopathological variables evaluated were age, tumor size, histological type, nuclear grade
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（NG）, ER /PR, HER2, Ki67, lymphovascular invasion, and lymph node metastasis.  Tissue 
specimens were stained immunohistochemically for PARP1 using antibodies obtained from Bethyl 
Laboratories location and an automated immunohistochemical assay（Ventana HX company）. 
After removal of paraffin, sections were washed and activated by heat treatment with EDTA. 
Endogenous peroxidase activity was inhibited by hydrogen peroxide solution, followed by 
blocking of non-specific protein binding.  The primary antibodies were diluted 1 :250, and the 
secondary antibodies were conjugated with biotin IgG.  Samples were visualized using avidin 
coupled with horseradish peroxidase, with diaminobenzidine as the chromogen, and enhanced by 
copper sulfate.  Finally, samples were dehydrated, cleared, and mounted after nuclear staining 
with hematoxylin, as described previously14，15）.  
　PAPR1 immunostaining was performed as described by von Minckwits et al 14） on sections 
containing the most invasive areas.  Areas showing the closest aggregation of positively stained 
cells（hot spot）at low magnification were selected for evaluation.  Cells showing positive staining 
were classified on the basis of the intensity of nuclear staining（i.e. percentage of positive cells）
as follows :（ⅰ）negative staining（0％ cells）;（ⅱ）weak staining（≥1％ to ＜10％ cells）;（ⅲ）
moderate staining（≥0％ to ＜50％ cells）; and（ⅳ）strong staining（≥50％ cells ; Fig. 2）.
　The ER/PR, HER2, and Ki67 status was evaluated as follows.  If ≥10％ of cells were 
positive for ER and PR, the specimen was defined as positive.  Being positive for HER2 was 
defined as IHC results with a score of 3＋（uniform intense membrane staining of ≥30％ of 
Fig. 1.  Loss of functional BRCA1 or BRCA2 
affects the choice of the DNA double-
strand break（DSB）repair pathway. DNA 
DSBs are repaired, in part, in normal 
cells by homologous recombination（HR）
-based mechanisms. Functional BRCA1 and 
BRCA2 proteins are required for efficient 
repair by HR and genomic stability. In the 
absence of BRCA1 or BRCA2, alternative 
repair pathways, such as non-homologous 
end-joining（NHEJ）and single-strand 
annealing（SSA）, are used, leading to cell 
death or survival with genomic damage10）.
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invasive tumor cells）according to the 2007 ASCO/College of American Pathologists guideline 
recommendations for HER2 staining 16）.  For Ki67, hot spot abnormalities were evaluated 
according to the percentage of stained cells（0％～100％, at 10％ intervals）.  The NG was 
determined as Grade 1, 2, or 3 from the sum of the nuclear atypia and mitotic count scores 
according to the General Rules for Clinical and Pathological Recording of Breast Cancer17）.  The 
presence or absence of lymph node metastasis was determined by hematoxylin-eosin staining and 
immunostaining for cytokeratin.  Positive lymph node metastasis was defined as the presence of 
micro- or macrometastasis（＞0.2 mm）, whereas the presence of isolated tumor cells（≤ 0.2 mm）
indicated negative lymph node metastasis.
　The classification of breast cancer subtypes in the present study was based on the expression 
patterns of HR（ER/PR）, HER2, and Ki67.  HR-positive breast cancer was defined as at least 
ER or PR positive.  In the present study, patients were classified into the following four groups :
（ⅰ）luminal A（HR positive, HER2 negative, Ki67 ＜20％）;（ⅱ）luminal B（HR positive, 
HER2 positive ; or HR positive, HER2 negative, Ki67 ≥20）;（ⅲ）HER2（HR negative, HER2 
positive）; or（ⅳ）triple negative（HR negative, HER2 negative）.  We also evaluated the 
clinicopathological features of the patients in each of these groups.
Statistical analysis
　Data among the four groups were compared using Chi-squared analysis for independence（2
×4 contingency table）.  Fisher’s exact probability test was used to determine the significance of 
differences between two groups.  Significance was set at P＜0.05.
Fig. 2.  Evaluation of poly ADP-ribose polymerase
（PARP）1 expression were classified into four 
groups :（ⅰ）negative staining（0％ cells）;（ⅱ）
weak staining（≥1％ to ＜10％ cells）;（ⅲ）
moderate staining（≥0％ to ＜50％ cells）; and
（ⅳ）strong staining（≥50％ cells）
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Ethics approval
　All patients provided informed consent for all investigations, including the retrieval of personal 
information from medical records.
Results
　The mean age for all 206 patients was 58.1 years（range 27～91 years）, with a mean tumor 
size of 2.03 cm（range 0.04～13.5 cm）.  Invasive breast cancer was identified histologically in 174 
patients（84.5％）, with the remaining 32 patients（15.5％）having other types of breast cancer. 
Vascular invasion was found in 46 patients（22.3％）.  The NG was estimated to be Grade 
1 in 99 patients（56.9％）cases, Grade 2 in 28 patients（16.1％）, and Grade 3 in 47 patients
（27.0％）.  Of the 206 patients in the study, 179（86.9％）were positive for HR and 27（13.1％）
were negative.  HER2 was positive in 30 patients（14.6％）and negative in 176 patients（85.4％）. 
Lymph node metastases were present in 60 patients（29.1％）and absent in 164 patients（70.9％）. 
Thirty-six patients were negative for PARP1 36（17.5％）, whereas 45（21.8％）, 53（25.7％）, and 
72（34.9％）patients exhibited weak, moderate, and strong PARP1 staining, respectively（Table 
1）.  Examination of the associations between PARP1 expression and clinicopathological features 
revealed that significantly more HR-positive patients were PARP1 negative（P＝0.0008 PARP 
negative vs. weak staining ; P＝0.0006 PARP negative vs. others）.  There were no significant 
differences for any of the other items evaluated（Tables 2，3）.
　The prevalence of the luminal A, luminal B, HER2, and triple-negative breast cancer subtypes 
was 54.4％（n＝112）, 32.5％（n＝67）, 5.8％（n＝12）, and 7.3％（n＝15）, respectively.  The 
proportion of patients with each of these subtypes exhibiting negative, weak, moderate, and 
strong PARP1 expression is given in Table 4.  There were no significant differences in the 
distribution of PARP1 expression among the four groups, although it is of note that there were 
no PARP1-negative patients in the triple-negative breast cancer group（Table 4）.
Discussion
　Previous studies have reported that the prevalence of luminal A plus B, HER2, and triple-
negative breast cancer subtypes is 60％～80％, 10％～15％, and 10％～20％, respectively 18，19）. 
In the present study, 86.8％ of breast cancers were luminal, 5.8％ were HER2 positive, and 
7.3％ were triple negative, indicating a higher proportion of patients with luminal breast cancer 
and a lower proportion of patients with triple-negative breast cancer.  This is most likely due 
to the fact that we excluded patients undergoing neoadjuvant therapies from the present study. 
Generally, patients with HER2-positive or triple-negative breast cancer are more likely to be 
undergoing neoadjuvant chemotherapies than patients with luminal-type breast cancer.
　PARP inhibitors are anticipated to be effective for triple-negative breast cancer because tumors 
harboring BRCA mutations have higher PARP activity 20，21）.  However, we did not find any 
significant differences in PARP expression between patients with triple-negative breast cancer 
and other breast cancer subtypes in the present study, although there were no PARP1-negative 
patients in the triple-negative group.  PARP1 negativity was significantly more common in the 
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ER/PR-positive patients.  One study as reported the absence of any correlation between PARP 
activity and PARP expression 22）.  The results of the present study suggest that PARP inhibitors 
may be ineffective for HR-positive breast cancers with BRCA mutations.  However, a Phase Ⅱ 
clinical trial of iniparib reported that the clinical benefit rate increased significantly from 34％ to 
56％（P＝0.01）when patients were treated with a combination of gemcitabine and carboplatin 23）. 
However, the effectiveness of PARP inhibitors has not been sufficiently established in currently 
ongoing clinical trials 24）.  A more in-depth analysis is required to determine the factors 
contributing to effective treatment.  Then we advocate that the effectiveness of these agents be 
Table 1.  Clinicopathological characteristics of the study subjects
Mean age（years） 58.1 （range: 27～ 91）
Mean of tumor size（cm） 2.03 （range: 0.04～ 13.5）
Histologic type
　Invasive ductal carcinoma 174 （84.5％）
　Special type 32 （15.5％）
Lymphovascular invasion
　negative 160 （77.7％）
　positive 46 （22.3％）
Nuclear grade
　1 99 （56.9％）
　2 28 （16.1％）
　3 47 （27％）
HR
　negative 27 （13.1％）
　positive 179 （85.4％）
HER2
　negative（score 0, 1, 2） 176 （85.4％）
　positive（score 3） 30 （14.6％）
Lymph node metastasis
　negative 146 （70.9％）
　positive 60 （29.1％）
Subtype
　Luminal A 112 （54.4％）
　Luminal B 67 （32.5％）
　HER2 12 （ 5.8％）
　Triple negative 15 （ 7.3％）
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Table 2.  Relationship between the intensity of nuclear staining for PARP1 and clinicopathological characteristics
PARP 1 negative（36） weak（45） moderate（53） strong（72）
Mean age（years） 59.0  （34～ 86） 58.6  （29～ 91） 56.5  （30～ 82） 58.4  （27～ 88）
Mean of tumor size（cm）  2.17（0.05～ 6.7）  2.03（0.2～ 9.0）  1.74（0.2～ 5.5）  2.13（0.04～ 13.5）
Histologic type
　Ductal type 33（91.7％） 37（82.2％） 42（79,2％） 62（86.1％）
　Special type  3（ 8.3％）  8（17.8％） 11（20.8％） 10（13.9％）
Lymphovascular Invasion
　Negative 28（77.8％） 37（81.2％） 42（79.2％） 56（77.8％）
　Positive  8（22.2％）  8（17.8％） 11（20.8％） 16（22.2％）
Nuclear grade
　1 23（63.9％） 22（48.9％） 30（56.6％） 46（63.9％）
　2  8（22.2％） 12（26.7％）  7（13.2％）  9（12.5％）
　3  5（13.9％） 11（24.4％） 16（30.9％） 17（23.6％）
HR
　Negative  1（ 2.8％） 12（26.7％）  7（13.2％）  8（11.1％）
　Positive 35（97.2％） 33（73.3％） 46（86.8％） 64（88.9％）
HER2
　Negative 33（91.7％） 35（77.8％） 47（88.7％） 61（84.7％）
　Positive  3（ 8.3％） 10（22.2％）  6（11.3％） 11（15.3％）
Lymph node metastasis
　Negative 23（53.9％） 36（80.0％） 36（67.9％） 51（70.8％）
　Positive 13（36.1％）  9（20.0％） 17（32.1％） 21（29.2％）
Table 3.  Relationship between the intensity of nuclear staining for  PARP1 and  HR status
PARP1 negative（36） weak（45） moderate（53） strong（72）
HR
　Negative  1（2.8％） 12（26.7％）  7（13.2％）  8（11.1％）
　Positive 35（97.2％） 33（73.3％） 46（86.8％） 64（88.9％）
＊＊P＝ 0.0047
＊P＝ 0.0342
＊P＜ 0.05, ＊P＜ 0.005 compared with negative PARP staining.
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examined in patients.
　There are several limitations to the present study.  The main weaknesses of the immuno-
histochemical approaches used herein are their limited technical reproducibility, subjective 
interpretation, and qualitative readouts.  Moreover, although we investigated PARP expression in 
the present study, we did not evaluate PARP activity.
　Future studies into the expression of PARP1 as a biomarker for the therapeutic activity of 
PARP inhibitor-based therapy should include more subjects with triple-negative breast cancer, as 
well as those with BRCA mutations.
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